Company research / MCRB

Seres Therapeutics, Inc. (MCRB)

CIK 0001609809 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

Partial revenue. In this company's filings, net income for the year ended 2025-12-31 is larger than reported revenue. The revenue it tags covers only part of its income (banks and REITs often tag only fee income this way, leaving out interest or rent), so it is not the company's whole top line. Margins on it are not computed, and it is left out of revenue rankings.

Key ratios (year ended 2025-12-31)

12.9%
Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-08-18

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Stock splits: 1-for-20, first reflected in a filing dated 2025-05-07. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$1.88M$789.0K$0$0$7.13M$144.93M$33.22M$34.51M$28.27M$32.10M$21.77M
R&D Expense$46.64M$49.06M$64.60M$117.60M$109.65M$141.89M$90.57M$80.14M$95.95M$89.45M$81.99M
Operating Income-$84.03M-$93.97M-$121.31M-$195.10M-$179.91M-$64.49M-$88.13M-$71.88M-$100.28M-$91.39M-$92.84M
Depreciation & Amortization$3.45M$4.13M$5.47M$6.24M$6.63M$5.95M$6.58M$7.60M$7.86M$7.26M$4.21M
EBITDA-$80.58M-$89.84M-$115.85M-$188.85M-$173.28M-$58.55M-$81.55M-$64.27M-$92.42M-$84.14M-$88.63M
Net Income-$22.46M$5.70M$136.0K-$113.72M-$250.16M-$65.58M-$89.13M-$70.28M-$98.94M-$89.38M-$91.58M
EPS (Diluted)n/a$0.64$0.00-$17.77-$2.31-$0.72-$1.12n/an/an/an/a
Total Assets$101.59M$138.19M$139.81M$358.60M$348.78M$354.86M$342.94M$132.44M$120.47M$189.52M$272.65M
Total Liabilities$67.05M$93.97M$126.03M$403.46M$338.00M$223.35M$168.19M$180.76M$168.52M$128.82M$140.01M
Long-Term Debtn/an/an/a$110.00M$50.00M$24.05M$25.00M$25.00Mn/an/an/a
Shareholders' Equity$34.53M$44.22M$13.78M-$44.86M$10.78M$131.51M$174.75M-$48.32M-$48.05M$60.70M$132.63M
Cash & Equivalents$15.59M$45.77M$30.79M$127.97M$163.03M$180.00M$116.05M$65.13M$85.82M$36.09M$54.54M
Operating Cash Flow-$51.26M$1.12M-$148.61M-$117.35M-$228.82M$6.69M-$93.61M-$76.52M-$62.85M-$75.52M$43.92M
Capital Expenditures$37.0K$252.0K$380.0K$7.97M$9.82M$9.57M$591.0K$1.00M$1.94M$4.68M$21.49M
Free Cash Flow-$51.30M$865.0K-$148.99M-$125.33M-$238.64M-$2.88M-$94.20M-$77.52M-$64.79M-$80.20M$22.43M
Share Repurchasesn/an/an/an/an/an/an/an/an/a$33.0Kn/a
Shares Outstanding9.83M9.56M8.65M135.04M125.22M91.89M91.46M70.14M40.94M40.57M40.36M
Weighted Average Diluted Sharesn/a8.87M7.77M6.40M108.08M91.70M79.79Mn/an/an/an/a
EPS (Basic)n/a$0.64$0.00-$17.77-$2.31-$0.72-$1.12n/an/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView